Arif, Ambreen
Hasnain, Aliya
Chaudhry, Auj
Asim, Muhammad
Shafqat, Muhammad Nabeel
Altaf, Abeer
Saba, Noor
Kemos, Polychronis
Ansari, M. Azim
Barnes, Eleanor
Metcalfe, Chris
Vickerman, Peter
Qureshi, Huma
Hamid, Saeed
Choudhry, Asad Ali
Niaz, Saad Khalid
Foster, Graham R.
Choudhry, Naheed
Funding for this research was provided by:
Wellcome Trust (220866/Z/20/Z, 220866/Z/20/Z, 220866/Z/20/Z, 220866/Z/20/Z, 220866/Z/20/Z, 220866/Z/20/Z, 220866/Z/20/Z, 220866/Z/20/Z, 220866/Z/20/Z, 220866/Z/20/Z, 220866/Z/20/Z, 220866/Z/20/Z, 220866/Z/20/Z, 220866/Z/20/Z, 220866/Z/20/Z, 220866/Z/20/Z, 220866/Z/20/Z, 220866/Z/20/Z)
Article History
Received: 4 September 2023
Accepted: 22 November 2023
First Online: 18 December 2023
Declarations
:
: The study is being conducted in accordance with the UK Policy Framework for Health and Social Care Research.This study was reviewed and approved by the Queen Mary Ethics Review Committee (Reference number QMERC20.306) on 27th May 2021, the Institutional Review Board of Aga Khan University (Reference number: 2021–6341-18329) on 29th June 2021 and Dow University of Health Sciences (Approval number: 2139/DUHS/Approval/2021/463) on June 12th 2021. The study was approved by the National Bioethics Committee (NBC) Pakistan (Ref: No.4–87/NBC-677/21/439) on 9th Sep 2021.This study was registered on clinicaltrials.gov (NCT04943588) on June 29, 2021.At enrollment, written informed consent will be obtained from all eligible participants after explaining details of the study and available treatment options and this will be confirmed by an independent witness.
: Not applicable.
: MAA, is supported by Sir Henry Dale Fellowship jointly funded by the Royal Society and Wellcome Trust (220171/Z/20/Z). EB, has received consultancy fees from Roche, AstraZeneca and Vaccitech. PV, has received unrestricted research funding from Gilead that is unrelated to this study. GRF, has received consultancy and speaker fees from Abbvie, Biomarin, CSL Behring, GSK, Gilead and Pfizer. None of the other authors have any competing interests to declare.